A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.

Item
http://www.wikidata.org/entity/Q35965525
Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective studyTherapeutic targets and new directions for antibodies developed for ovarian cancer.Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer ModelsInterim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagementSystemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.CA125 effects on humoral immunosuppression.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer.CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast CancerLeveraging PET to image folate receptor α therapy of an antibody-drug conjugate
P2860

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.

Item
http://www.wikidata.org/entity/Q35965525
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A Randomized, Double-Blind, Pl ...... st Platinum-Sensitive Relapse.
@ast
A Randomized, Double-Blind, Pl ...... st Platinum-Sensitive Relapse.
@en
type
label
A Randomized, Double-Blind, Pl ...... st Platinum-Sensitive Relapse.
@ast
A Randomized, Double-Blind, Pl ...... st Platinum-Sensitive Relapse.
@en
prefLabel
A Randomized, Double-Blind, Pl ...... st Platinum-Sensitive Relapse.
@ast
A Randomized, Double-Blind, Pl ...... st Platinum-Sensitive Relapse.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
A Randomized, Double-Blind, Pl ...... st Platinum-Sensitive Relapse.
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921